Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

ALZA/MERCK ONCE-DAILY DILTIAZEM AND DILTIAZEM/VASOTEC COMBO are being "clinically evaluated" by Merck, Alza said March 8. The drug delivery technology firm Alza and the cardiovascular leader Merck have a licensing agreement covering the calcium channel blocker diltiazem (Marion Merrell Dow's Cardizem) and a diltiazem/enalapril (Merck's ACE inhibitor Vasotec) combo in once-a-day oral dosage forms. The dosage forms employ an osmotic controlled-release technology to which both firms contributed. Alza is not specifying if the technology is based on its proprietary Oros osmotic release system. Neither is Alza disclosing at what stage the products are in the development process. Merck would market both products worldwide under a royalty-bearing agreement with Alza. Importantly for Alza, the agreement would allow the firm to retain some undisclosed U.S. marketing rights. The licensing agreement is several years old but was not previously disclosed by Alza in public presentations. The renewal of joint development efforts by Alza and Merck indicates a rapprochement between the two firms after a fall-out over Merck's 1983 European market withdrawal of the Oros-system indomethacin product Osmocin. Merck withdrew the product and dropped U.S. development efforts after adverse reaction reports in Europe ("The Pink Sheet" Jan. 23, 1984, T&G-4). A sustained-release diltiazem would fill one of the few remaining gaps in Merck's strong cardiovascular armamentarium. The company is lacking an approved calcium channel blocker at the moment; an NDA is pending for Splendil (felodipine, formerly dubbed Plendil) for hypertension. Merck already markets two ACE inhibitors, Vasotec and Prinivil; the beta blocker Blocadren; the anti-arrhythmic Tonocard; the potassium-sparing diuretic Moduretic; and the older antihypertensive Aldomet. Alza/Merck is in a race with a number of competitors for once-daily diltiazem, including Marion Merrell Dow and Rorer, which maintains a joint venture with Bolar for a once-a-day product ("The Pink Sheet" July 24, T&G-6). Exclusivity for immediate release Cardizem expires Nov. 5, 1992, and protection for the twice-daily product, Cardizem SR, runs out in 1993. Also working on once-a-day diltiazem is Elan, which is working with Marion Merrell Dow on Diltelan; Noven is in early development for another transdermal form, and Verex is developing a once-daily form called Verzem.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts